OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
Researchers at the Cedars-Sinai Medical Center in Los Angeles set out to see if there are any health benefits to be derived from a massage, or is a massage just relaxing to your muscles? […]
All the drugs used as 2nd line hormone therapy are only partially effective. Only some individuals respond and receive any benefit from them, but there has been some recent research into combining the drugs. At the last American Society of Clinical Oncology (ASCO), Dr. Eric Small, M.D. presented a abstract about his recent experimentation of [...]
Somastatin is a naturally occurring hormone that affects the levels of other hormone production in the body. Its most common drug use today is to treat giantism and acromegaley, a disease characterized by an over abundance of growth hormones. There is laboratory evidence that somastatin analogs such as octreotide acetate (Sandostatin/Sandoz) can affect the growth [...]
Leukine, a granulocyte macrophage colony-stimulating factor (GM-CSF), is a hormone therapy that does not have an effect on a man’s testosterone production. Leukine is used by many physicians who are knowledgeable about the value of second line hormone therapy. Leukine works by stimulating the white blood cells (both increasing the overall production of the white [...]